Full-Time

Regulatory Operations Expert

Updated on 8/1/2026

Fortrea

Fortrea

10,001+ employees

Global CRO providing Phase I-IV trials

No salary listed

Mumbai, Maharashtra, India

Hybrid

Hybrid role with 5–10% regional or global travel, including occasional overnight stays.

Category
Legal & Compliance (1)
Required Skills
Microsoft Office
Data Analysis

Get referred to Fortrea

See people who can refer or advise you

Requirements
  • A Bachelor’s in Pharmacy or a related science degree, or an advanced degree such as a PhD or Master’s, is required; relevant and equivalent experience and successful project outcomes may be accepted in lieu of educational requirements.
  • An advanced degree (MSc or PhD) in Chemistry, Chemical Engineering, Material Science, or Pharmaceutical Sciences is required.
  • Experience of at least 7–9 years in the job discipline, including Regulatory Affairs, Quality Assurance, Analytical Science, Packaging, Polymer and/or Pharmaceutics, material management, drug development, and manufacturing processes, is required.
  • Strong hands-on scientific understanding of analytical chemistry and material characterization is required.
  • Strong hands-on understanding of organic and inorganic chemistry relevant to pharmaceutical materials is required.
  • Strong hands-on understanding of pharmaceutical manufacturing processes and unit operations is required.
  • Demonstrated experience in CMC-relevant scientific documentation, including material qualification and risk assessments, comparability and lifecycle justifications, and regulatory-facing scientific narratives, is required.
  • The ability to independently analyze complex datasets, draw defensible conclusions, and clearly articulate scientific rationale is required.
  • Familiarity with pharmaceutical compliance, including GMP expectations for materials, suppliers, and lifecycle change control, is required.
  • Technical proficiency with Microsoft Office applications and document management and/or publishing tools is required.
  • Innovation, proactive ownership, precision, and goal orientation are required.
  • Leadership, problem-solving, and interpersonal skills are required.
  • Good organizational and time-management ability is required.
  • Good analytical capabilities and customer focus are required.
  • Good review skills and concern for quality are required.
  • The ability to address internal and external audit situations is required.
  • Excellent command of written and spoken English and/or other applicable languages is required.
Responsibilities
  • Act as the scientific owner for high-quality CMC documentation concerning pharmaceutical raw materials and excipients, process aids and contact materials including leachables and extractables, and material changes, supplier changes, and lifecycle optimization activities.
  • Translate complex analytical, chemical, and manufacturing data into scientifically rigorous justifications, risk assessments, material qualification reports, and CMC sections supporting variations, supplements, and regulatory responses.
  • Ensure scientific content aligns with Quality-by-Design principles and supports control strategies, defined design space and material-attribute justifications, and lifecycle change management.
  • Integrate and critically interpret analytical chemistry data, including physicochemical characterization, impurity and degradation profiles, elemental and inorganic contaminants, and comparability and trend analyses.
  • Apply organic and inorganic chemistry principles to assess material composition, chemical reactivity, and degradation pathways; evaluate compatibility with formulations, processes, and packaging systems; and support impurity and risk justifications.
  • Identify analytical data gaps and define scientifically appropriate strategies to close them in collaboration with analytical development and external laboratories.
  • Provide scientific assessments of the impact of material attributes on pharmaceutical manufacturing processes and unit operations, including blending, granulation, drying, compression, coating, mixing, filtration, emulsification, and sterilization as applicable.
  • Support technology transfer, Process Performance Qualification, and commercial manufacturing by documenting material-process interactions, supporting root cause investigations and comparability assessments, and providing scientific rationales for process or material changes.
  • Ensure scientific conclusions reflect manufacturing reality, robustness, and process capability rather than laboratory observations alone.
  • Ensure documentation aligns with global regulatory and compliance expectations, including ICH Q8–Q12 principles, pharmacopeial requirements, and GMP expectations for materials, suppliers, and change management.
  • Support regulatory submissions, variations, and health-authority interactions by providing clear, defensible scientific rationales and ensuring consistency between analytical data, process understanding, and CMC narratives.
  • Maintain traceability between experimental data, conclusions, and regulatory positions throughout the product lifecycle.
  • Act as a scientific interface between MSAT, Analytical Development, Formulation, Manufacturing, Quality, and Regulatory Affairs.
  • Engage with external suppliers, contract laboratories, and technical experts to clarify chemistry- and material-related questions, challenge data quality where needed, and ensure completeness and scientific credibility of external information.
  • Contribute to knowledge management within MSAT by ensuring scientific learnings are captured in a reusable, lifecycle-oriented manner.
Desired Qualifications
  • At least 1 year of experience in project management is desirable.
  • Knowledge of Management Information Systems and electronic data management systems, such as Regulatory Information Management systems, is preferred.
  • A diploma or certification in Regulatory Affairs is preferred.
  • A Bachelor’s in Pharmacy or related science degree, or an advanced degree such as a PhD or Master’s, with 7–9 years of relevant experience is preferred.
  • An advanced degree (MSc or PhD) in Chemistry, Chemical Engineering, Material Science, or Pharmaceutical Sciences is preferred.
  • A strong understanding of the pharmaceutical product lifecycle, regulatory requirements, GxP, and ICH-GCP guidelines is desirable.
  • A scientist mindset with ownership and accountability for scientific quality is preferred.
  • Analytical, structured, and rigorous data interpretation and verification are preferred.
  • Proactive and confident engagement with senior scientific, manufacturing, and regulatory stakeholders is preferred.
  • The ability to convert complex science into globally aligned, regulator-ready CMC knowledge is preferred.

Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

2023

Get referred to Fortrea

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fortrea reaffirmed 2026 revenue guidance of $2.55 billion to $2.65 billion.
  • Fortrea reaffirmed 2026 adjusted EBITDA guidance of $190 million to $220 million.
  • Leadership stability and inducement awards support finance execution and retention.

What critics are saying

  • CFO turnover can disrupt budgeting, forecasting, and investor messaging.
  • Guidance leaves little room for trial delays or client pushouts.
  • The stock's elevated valuation magnifies disappointment from any execution miss.

What makes Fortrea unique

  • Fortrea named Jason Knoblauch CFO on July 6, 2026.
  • Knoblauch brings CFO experience from Clario and Curia.
  • McConnell stays through transition, supporting financial continuity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

27%

1 year growth

27%

2 year growth

27%
Connectweb Technologies, Inc.
Apr 7th, 2026
Fortrea unveils Fortrea Intelligent Technology(TM) to help sponsors and sites run Smarter, more integrated trials.

Fortrea unveils Fortrea Intelligent Technology(TM) to help sponsors and sites run Smarter, more integrated trials. Fortrea Holdings Inc AI-enhanced suite of solutions features new and improved technology to empower efficiency, confidence and quality. Highlights: * Designed to transform clinical trial operations for sponsors, sites and study teams * Persona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and quality * Builds on Fortrea's flagship platform Xcellerate(R) to deliver near-real-time, role-based insights DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) - Fortrea (Nasdaq: FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology(TM)(FIT), a suite of innovative technology solutions designed to transform clinical trial operations. By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversight and elevate productivity, FIT helps enable sponsors, investigator sites and Fortrea project teams to deliver trials faster, with greater predictability, agility and quality. An Innovative, Intelligent Suite of Clinical Solutions FIT encompasses major enhancements to familiar Fortrea offerings, including the award-winning Xcellerate(R) platform, along with newly launched solutions designed to integrate all processes within the trial ecosystem. The suite boasts applications for biopharma and biotech customers across clinical pharmacology, clinical development and medical device development, and it can be deployed in both full service and functional service models, with select components available as software-as-a service (SaaS). FIT solutions are arranged into three pillars: * Lifecycle: Deliver Trials Faster with Confidence Solutions that help sponsors and sites progress clinical trials throughout each step of the clinical development journey. They help accelerate clinical trials by automating key steps, from pre-award to final eTMF. * Foresight: Turn Data into Actionable Insights Solutions that transform data into foresight, helping enable faster decision-making and proactive risk mitigation. They provide clarity, trend analysis and risk mitigation through intuitive dashboards that empower confident, near-real-time decisions and simplified oversight. * Companion: Empowering Study Teams to Work Smarter Persona-driven, AI-powered solutions that support more productive and efficient clinical trial operations. They help streamline study delivery, help boost productivity and enable collaboration. "We are at a remarkable moment in time, where the evolution of clinical trials is converging with unprecedented advancements in technology. Fortrea Intelligent Technology sits at this nexus," said Chief Information Officer Alejandro Martinez Galindo. "Built on decades of industry experience and direct sponsor and investigator site input, FIT delivers human-centered solutions that enable sponsors and sites to conduct trials more efficiently, with greater confidence and lower risk." Xcellerate(R) Anchors the Intelligent Suite Xcellerate(R), Fortrea's platform for Risk-Based Quality Management (RBQM), Central Monitoring and Oversight, is the foundation of the FIT offering. Recent enhancements deliver a modern, intuitive experience that integrates data across the trial ecosystem to provide near-real-time, role-based insights. With embedded AI and machine learning, Xcellerate(R) can analyze complex patterns, generate predictive signals and initiate automated workflows, reducing manual effort and enabling teams to focus on the critical human judgment required for successful clinical research. "We expect these Xcellerate(R) enhancements and the broader FIT platform will be game changers for our study teams and our clients," said Chief Operating Officer and President, Clinical Development Mark Morais. "Incorporating the responsible and ethical use of AI, these technologies enable a stronger research ecosystem and the ability to respond more quickly to what the data are telling us - all of which can make the difference in getting life-changing treatments to patients faster and more efficiently." Fortrea continues to expand the Fortrea Intelligent Technology portfolio, with additional solutions planned for future release. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. Connectweb partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Its talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow Connectweb on LinkedIn, X and Bluesky. Fortrea Contacts: Jennifer Minx (Media) - 919-410-4195, [email protected] Kate Dillon (Media) - 646-818-9115, [email protected] Tracy Krumme (Investors) - 984-385-6707, [email protected]

Yahoo Finance
Apr 7th, 2026
Fortrea launches AI-powered technology suite to speed up clinical trials

Fortrea, a global clinical research organisation, has unveiled Fortrea Intelligent Technology (FIT), an AI-enhanced suite of solutions designed to transform clinical trial operations for sponsors, sites and study teams. The platform builds on Fortrea's Xcellerate system to deliver persona-driven, AI-powered solutions that automate workflows and streamline oversight. FIT is organised into three pillars: Lifecycle, which accelerates trials from pre-award to final eTMF; Foresight, providing near-real-time insights and risk mitigation through intuitive dashboards; and Companion, offering AI-powered tools to boost productivity and collaboration. The suite is available for clinical pharmacology, clinical development and medical device development, deployable in full service and functional service models, with select components available as software-as-a-service.

Yahoo Finance
Feb 26th, 2026
Fortrea reports $2.7B revenue, $190M EBITDA as book-to-bill hits 1.14x

Fortrea reported Q4 revenue of $660.5 million, down 5.2% year-over-year, and full-year revenue of $2.723 billion, up 1% and within guidance. Q4 adjusted EBITDA was $54 million, whilst full-year adjusted EBITDA reached $189.9 million. The company posted a Q4 GAAP net loss of $32.5 million. Management noted improving demand, with Q4 book-to-bill at 1.14x and backlog at $7.7 billion, driven by higher client engagement and increased biotech RFP flow. Fortrea exceeded cost-savings targets, delivering $153 million gross savings, and generated strong Q4 operating cash flow of $129.1 million. The company repurchased $75.7 million of senior notes and ended with over $600 million liquidity. For 2026, Fortrea guided revenue of $2.55–2.65 billion with adjusted EBITDA of $190–220 million.

Yahoo Finance
Feb 25th, 2026
Fortrea reports Q4 results tomorrow with revenue expected to decline 4.3% year on year

Clinical research company Fortrea Holdings reports Q4 earnings tomorrow. Analysts expect revenues to decline 4.3% year on year, following a 1.8% decrease in the same quarter last year. Last quarter, Fortrea beat revenue expectations with $701.3 million, up 3.9% year on year, and issued full-year guidance exceeding analysts' forecasts. However, the company has missed Wall Street's revenue estimates multiple times over the past two years. Analysts have largely maintained their estimates over the last 30 days. Shares have declined 36.8% over the past month, underperforming the drug development inputs and services segment, which averaged a 1.1% decline. The stock currently trades at $10.98 against an average analyst price target of $16.44.

The Associated Press
Feb 17th, 2026
Fortrea appoints Oren Cohen as chief medical officer and Scott Dove as president of Clinical Pharmacology Services

Fortrea, a global contract research organisation, has expanded its executive team with two appointments. Oren Cohen, who previously served as both chief medical officer and president of Clinical Pharmacology Services, will now focus solely on his CMO responsibilities, overseeing medical strategy, scientific leadership and governance across Fortrea's portfolio. Scott Dove has joined as president of Clinical Pharmacology Services, responsible for early clinical development solutions across Fortrea's global network. Dove brings over 25 years of drug development experience, most recently serving as chief operating officer at Aravive and holding leadership roles at PPD, Allergan and Furiex Pharmaceuticals. Both Cohen and Dove serve on Fortrea's Executive Committee. The company provides clinical trial management and consulting services across more than 20 therapeutic areas.